ArticleJournal of personalized medicine2023
Clinical Asthma Remission Obtained with Biologics in Real Life: Patients' Prevalence and Characteristics.
Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors.Allergy · 2026Review
- Early response toward clinical remission with dupilumab in severe asthma: Real-world cohort.The journal of allergy and clinical immunology. Global · 2026Article
- Observational
- The Impact of BMI on the Effect of Biologic Agents for Severe Asthma.Pulmonary therapy · 2026Review
- Evaluation of the concordance of asthma remission definitions according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma.Frontiers in pharmacology · 2026Article
- Determinants of Clinical Remission in Dupilumab-Treated Severe Eosinophilic Asthma: A Real-World Retrospective Study.Biomedicines · 2025Article
- Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion.Respirology (Carlton, Vic.) · 2025Review
- Achieving remission in severe asthma.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission.BMC pulmonary medicine · 2025Article
- Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study.Journal of clinical medicine · 2025Article
- On-treatment clinical remission of severe asthma with real-world longer-term biologic use.The journal of allergy and clinical immunology. Global · 2025Article
- Clinical Remission Predictors in Non-Colonized Bronchiectasis and Severe Asthma with Type 2-Targeted Biologic Therapy: A Retrospective Real-Life Pilot Study.Journal of clinical medicine · 2024Article
- Epigenetic patient stratification via contrastive machine learning refines hallmark biomarkers in minoritized children with asthma.Research square · 2024Article
- Exploring Clinical Remission in Moderate Asthma - Perspectives from Asia, the Middle East, and South America.Pulmonary therapy · 2024Article
- Clinical remission and control in severe asthma: agreements and disagreements.Drugs in context · 2024Review
- Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.Frontiers in immunology · 2024Article
- Degree of Adherence to Recommendations From the Spanish Consensus on the Reduction of Oral Corticosteroid Use in Asthma Patients: A Questionnaire-based Observational Study.Open respiratory archivesArticle
- Challenges in the Implementation of the Spanish Consensus on the Reduction of Oral Corticosteroids: Insights From the Medical Community.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of clinical asthma remission with biologics in severe asthma has not been well understood yet. We do not even know whether there might be characteristics that identify subjects prone to remission of the disease. MATERIALS AND
methodsRetrospectively, four groups of severe asthmatics already treated with Omalizumab, Mepolizumab, Benralizumab and Dupilumab (302, 55, 95 and 34 patients, respectively) for at least 12 months were considered. The number of individuals with clinical asthma remission was sought in each group. This was considered when patients, after a treatment of at least 1 year with one of the aforesaid biologics, showed the disappearance of asthma symptoms (ACT ≥ 20), zero exacerbations, suspension of oral corticosteroids and a FEV
resultsThe prevalence of asthma remission after a mean of 37.8 ± 19.2, 13.5 ± 1.7, 15.4 ± 5.5 and 12 ± 0 months of Omalizumab, Mepolizumab, Benralizumab and Dupilumab treatments was 21.8%, 23.6%, 35.8% and 23.5%, respectively. For each biologic, different baseline characteristics, seem to be associated with failure to achieve clinical asthma remission. Older age, higher BMI, a later age of asthma onset, rhinitis/sinusitis/nasal polyposis, comorbidities and a greater asthma severity may be the characteristics of a suboptimal response to biologic treatments.
conclusionAll biologics have the potential to induce disease remission in severe asthmatics. For each biologic, there may be several markers that can identify the patients who will not achieve asthma remission. It would be important to detect them (by carrying out targeted studies) as they would allow us to select the best biologic that may induce clinical asthma remission on a larger number of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.